… American Academy of Optometry (AAOpt) Annual Meeting 2020 American Academy of … 2020 ProQR to participate in the American Academy of Optometry (AAOpt) Annual Meeting 2020 . Qua, 07/10/2020 - …
… Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Applicability … J Boudet et al. A robust computational approach is developed to screen for compatible interactions between …
… Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares LEIDEN, The Netherlands, … 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
